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Abstract
OBJECTIVE: To observe the clinical efficacy of Busu-
ishengxue granules on non-severe aplastic anemia
(NSAA) and investigate its effect on the mitogen-ac-
tivated protein kinase/extracellular signal-regulat-
ed kinase (MAPK/ERK) pathway.
METHODS: Sixty NSAA patients were divided
equally into two groups. Subjects in the experimen-
tal group were treated with Busuishengxue gran-
ules, and the control group with Zaizaoshengxue
tablets. The treatment course was 6 months and cu-
rative efficacy was compared between the two
groups as well as with 10 healthy individuals. Flow
cytometry (FCM) was used to detect the intracellu-
lar concentration of Ca2 + ([Ca2 + ]i). Western blotting
was employed to detect the expression of enzymes
in the MAPK/ERK pathway.
RESULTS: The efficacy of Busuishengxue granules
was significantly better than that of Zaizaoshengx-
ue tablets (P<0.05). Before treatment, expression of
JNK, phospho-ERK 1/2 and p-JNK was higher, and
[Ca2 + ]i higher, than that of the control group (P<
0.05). After treatment with Busuishengxue gran-
ules, expression of all enzymes related to signal
transduction pathways in the blood cells of NSSA
patients were altered to different degrees.
CONCLUSION: Busuishengxue granules had a bet-
ter effect with regard to improving symptom
scores, increasing the number of blood leukocytes,
and increasing hemoglobin levels than Zaizaosh-
engxue tablets, and they differed slightly in terms
of increasing the number of platelets.
© 2014 JTCM. All rights reserved.
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INDRODUCTION
Aplastic anemia (AA) is a disease in which the bone
marrow (BM) is damaged. This causes a deficiency of
red blood cells (RBCs), white blood cells (WBCs), and
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platelets. AA can be classified as severe aplastic anemia
and non-severe aplastic anemia (NSAA). The prolifera-
tion, differentiation and release of hematopoietic stem
cells in the BM is achieved by the combination of he-
matopoietic stem-cell adhesion molecules, stromal
cells, and adhesion proteins of the extracellular matrix.1
Traditional Chinese Medicine (TCM) for AA has been
used for many years. In patients with AA, TCM can be
used to: regulate imbalances in the immune system;
promote the proliferation and differentiation of stem
cells; improve the hematopoietic microenvironment.
As shown in our preliminary study, the abnormal adhe-
sion and abnormal expression of integrins from the
very late activation antigen (VLA) subfamily are closely
related to NSAA. Abnormal expression of adhesion
molecules such as VLA-2, VLA-4, VLA-5 and VLA-6
seemed to be implicated in NSAA. Levels of these adhe-
sion molecules seem to differ before and after treat-
ment with TCMs.2-8 We inferred that abnormal expres-
sion of integrins from the VLA subfamily may be
caused by abnormal expression of the intracellular sig-
naling pathways mediated by them, especially the mito-
gen-activated protein kinase/extracellular signal-regulat-
ed kinase (MAPK/ERK) pathway. Hence, we investi-
gated the enzymes of the MAPK/ERK pathway as well
as intracellular levels of the calcium ion ([Ca2+]i) to un-
derstand how treatment with TCM affects this path-
way in patients with NSAA.
MATERIALS ANDMETHODS
Subjects
The study cohort was 60 subjects with NSAA. They
were inpatients or outpatients from the Number One
Hospital of the Heilongjiang University of Chinese
Medicine (Heilongjiang, China) from November 2008
to April 2012. All subjects participated voluntarily in
this study and provided written informed consent.
They were divided randomly into the experimental
group and control group. There were 30 patients (16
males and 14 females) in the experimental group and
they were aged 14-67 (mean age, 36 ±8) years. There
were 30 cases (15 males and 15 females) aged 14-65
(mean age, 35 ± 8) years in the in the control group.
Ten healthy volunteers (5 males and 5 females) with a
mean age of (28±7) years served as the normal group.
The duration of NSAA ranged from 6 months to 25
years.
Criteria for inclusion or exclusion into the study
Inclusion criteria: all subjects had primary NSAA. The
diagnosis and decisions regarding curative effect were
based on a Chinese publication: blood disease diagno-
sis and treatment standards.9
Exclusion criteria: the following subjects were exclud-
ed: pregnant or lactating women; those who could ex-
press themselves; patients with incomplete clinical da-
ta; those with insufficient cure (less than six months);
patients who did not comply with treatment, who
withdrew from the study, or who were involved in oth-
er clinical trials; subjects with severe and uncontrolla-
ble bleeding/infection; those who had other blood dis-
eases or malignant diseases.10
Treatments
The experimental group underwent treatment with Bu-
suishengxue granules. Each granule contains Shudi-
huang (Radix Rehmanniae Preparata), Shanyurou (Fruc-
tus Corni), Gouqizi (Fructus Lycii), Yinyanghuo (Herba
Epimedii), Bajitian (Radix Morindae Officinalis), Lu-
rong (Cornu Cervi Pantotrichum), Renshen (Radix Gin-
seng), Huangqi (Radix Astragali), Danshen (Radix et
Rhizoma Salviae Miltiorrhizae), Jixueteng (Caulis
Spatholobi), Baihuasheshecao (Herba Hedyotis Diffu-
sae), and Zhuling (Polyporus). Busuishengxue granules
were prepared by the Pharmaceutical Factory of the
First Affiliated Hospital, Heilongjiang University of
Chinese Medicine (lot number: 19970048; 15 g/bag).
After being dissolved in water, one bag was taken three
times daily via the oral route.11
The control group was treated with Zaizaoshengxue
tablets (5 tablets on each occasion, three times daily).
Zaizaoshengxue is a patented medicine in China ap-
proved by the State Food and Drug Administration
(SFDA) for AA treatment. Each tablet comprises Tusizi
(Semen Cuscutae), Hongshen (Radix Ginseng Rubra),
Ejiao (Colla Corii Asini), Huangqi (Radix Astragali
Mongolici), Danggui (Radix Angelicae Sinensis), Shudi-
huang (Radix Rehmanniae Praeparata), Heshouwu (Ra-
dix Polygoni Multiflori stir-fried), Yinyanghuo (Herba
Epimedii Brevicornus), Huangjing (Rhizoma Polygonati
Sibirici), Lurong (Cornu Cervi Pantotrichum), Xianhe-
cao (Herba Agrimoniae) and Gouqizi (Fructus Lycii). It
was produced by Liaoyuan Yadong Pharmaceutical Fac-
tory (Jilin Province, China; SFDA approval number,
Z22025856; 0.35 g/tablet).
Both groups were treated for 3 months as one course.
A follow-up of 12 months was conducted.
Measurements
Symptoms were scored according to guidelines for clin-
ical research for TCMs.12 The symptoms to be scored
were: heart palpitations; dizziness; fatigue; pale face,
mouth, lips and nails; night sweats; bleeding; cold pe-
ripheries; soreness and weakness of the waist and
knees; fever; feverish palms and soles; thirst; dry stools;
and loose stools. "0" denoted no symptoms, "1" slight
symptoms, "2" medium symptoms, and "3" severe
symptoms.
Determination of curative efficacy was based on a Chi-
nese publication: blood disease diagnosis and treat-
ment standards.9 Four levelswere used, as listed below.
(a) Basic recovery: symptoms of anemia and bleeding
disappeared. Hemoglobin (HB) level for a male was ≥
120 g/L and for a female was ≥100 g/L;WBCs ≥4×109/L;
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platelets ≥80×109/L. No recurrence at >12-month fol-
low-up.
(b) Remission: the symptoms of anemia and bleeding
disappeared. HB level for a male was ≥120 g /L and for
a female was ≥100 g/L; WBCs ≥3.5×109/L; platelets in-
creased to some degree. The condition is stable or im-
proving at 3-month follow-up.
(c) Significant improvement: the symptoms of anemia
and bleeding improved significantly. Under a condi-
tion of no blood transfusion, the HB common increas-
es to >30 g/L compared with 1 month before treat-
ment and is maintained for ≥3 months. Those who ful-
filled i-iii should not be transfused for 3 months.
(d) No effect: there was no significant improvement in
symptoms and hemograms after treatment.11
Reagents and solutions
The medium for separating human lymphocytes was
purchased from Tianjin Hao Yang Biological (Tianjin,
China). Fluo-3-AM was from Signalway Antibody
(College Park, MD, USA), as were monoclonal anti-
bodies against p-JNK, p-p38 and p-ERK. β-actin and
western blotting chemiluminescence solution were also
from Signalway Antibody. Horseradish peroxidase
(HRP)-labeled goat anti-rabbit immunoglobulin (Ig) G
was from Beijing Zhongshan Golden Bridge Company
(Beijing, China). Developing solution, fixer and
X-OMAT BT film (5×7 in) were from Eastman Kodak
(New York, NY, USA).
Detection methods
Flow cytometry can be used to detect [Ca2+]i with lym-
phocyte separating medium. In this way, bone marrow
mononuclear cells (BMMCs) were separated. Based on
a Fluo-3-AM assay kit, Ca2 + in BMMCs was stained,
and the separated BMMCs divided into tubes A and B.
D-PBS (Dulbecco's Phosphate-Buffered Saline) was
added to tube A, and Fluo-3AM to tube B. Both tubes
were incubated in the dark for 1 h. Flow cytometry
was then carried out on both tubes.
Western blotting was employed to detect the expres-
sion of enzymes and phosphorylation level. BMMCs
were cultured in cell dishes. They were then rinsed
with phosphate-buffered saline (PBS) and added to cell
lysates. Cells were scraped and collected in 1.5 mL mi-
crocentrifuge tubes. This was followed by placement in
a hot water bath for 5-10 min and centrifugation at
120 000 rpm for 10 min. The supernatant was re-
moved to measure protein content using the Bradford
method. Protein (50 μg) was taken from each sample
to add to 2× sample buffer to conduct discontinuous
sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (separation gel, 100 g/L; spacer gel, 60 g/L). After
electrophoresis, protein in the gel was electrotrans-
ferred to nitrocellulose membranes. Bovine serum albu-
min (10 g/L) was added drop-wise. Primary antibody
(rabbit anti-ERK or rabbit anti-ERK antibody, work-
ing concentrations for both were 1∶1000 dilution) and
secondary antibody (HRP-labelled goat-anti-rabbit
IgG at 1∶3000 dilution) were added in order, and al-
lowed to react for 1 h and 2 h, respectively. After wash-
ing membranes, detection was by ECL chemilumines-
cence (i.e., we developed an X-ray film for 2-20 min).
The results after fixation were observed. The detection
methods and monitoring of other indices were the
same as described above.
Statistical analyses
Data are the mean±standard deviation ( xˉ ± s). Group
comparisons were tested by the Student's t-test. SPSS
ver 13.0 (SPSS, Chicago, IL, USA) was employed to
analyze data. P<0.05 was considered significant.
RESULTS
Curative efficacy of the experimental group and
control group
The total efficacy of Busuishengxue granules and Zaiza-
oshengxue tablets was 80.0% and 53.3% respectively,
and showed significant difference (P<0.05) (Table 1).
Symptom scores of the two groups before and after
treatment
There was no significant difference between the two
groups before treatment, but differences existed before
and after treatment in both groups (P<0.05). There
was a significant difference between the two groups af-
ter treatment (P<0.05)(Table 2).
Comparison of the peripheral blood of patients in
the experimental group and control group
In peripheral blood, levels of WBC, HB and platelets
in both groups after treatment increased compared
with those before treatment (P<0.05). After treatment,
platelet number was not significantly different (P>
0.05), whereas WBCs and HB in the experimental
group were significantly higher than those in the con-
trol group (P<0.05) (Table 3).
Group
Experimental
Control
n
30
30
Basic recovery
0
0
Remission
14 (46.7)
4 (13.3)
Significant improvement
10 (33.3)
12 (40.0)
No effect
0
14 (46.7)
Total efficacy
24 (80.0)a
16 (53.3)
Table 1 Curative efficacy of the experimental group and control group [n (%)]
Notes: the experimental group was treated with Busuishengxue granules (15 g/bag) three times daily. The control group was treated with
Zaizaoshengxue tablets (5 tablets on each occasion, three times daily). Both groups were treated for 3 months as one course. A follow-up of
12 months was conducted. Comparison of the efficacy between the two groups is given by aP<0.05.
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Distribution of calcium ions and levels of bone mar-
row mononuclear cells in the experimental group and
control group before and after treatment (Figure 1, Ta-
ble 4)
The [Ca2+]i in BMMCs of the experimental group and
control group before treatment was higher than that of
the normal group (P<0.0, Tables 4 and 5), whereas the
[Ca2+]i of the experimental group did not differ signifi-
cantly from that of the control group (P>0.05). After
treatment, the [Ca2 + ]i in BMMCs decreased compared
with that before treatment (P<0.05). The experimental
group had better recovery than that of the control
group (P<0.05).
MAPK/ERK pathway-related enzyme expression in
bone marrow mononuclear cells
Expression of p-ERK1/2 protein in the experimental
group and control group before treatment was signifi-
cantly lower than that of the normal group (P<0.05,
Table 5). There was no significant difference between
the experimental group and control group before treat-
ment (P>0.05). Expression of p- (extracellular regulat-
ed kinase) ERK1/2 in the experimental group and con-
trol group increased after treatment, differing signifi-
cantly from that before treatment (P<0.05). There was
a significant difference between the experimental group
and control group after treatment (P<0.05), as well as
with the normal group (P<0.05).
Expression of ERK1/2 protein in the experimental
group and control group was lower than that of the
normal group (P<0.01, Table 6), and the difference be-
tween the groups was significant (P>0.05). Expression
after treatment in the experimental and control groups
recovered to some degree, and the difference between
groups was marked (P<0.05). The difference before
and after treatment in the experimental group was sig-
nificant (P<0.05), and was also significantly different
from that of the normal group (P<0.01).
Expression of ERK2 protein in the experimental group
and control group before treatment was significantly
lower than that of the normal group (P<0.05, Table 7).
ERK2 expression in the experimental group and con-
trol group after treatment increased significantly from
Group
Experimental
Control
n
30
30
Treatment
Before treatment
After treatment
Before treatment
After treatment
WBC (×109）
2.4±0.4
3.5±1.0ab
2.6±0.8
3.0±1.1a
HB (g/L)
59.2±17.2
87.1±18.5ab
61.8±18.4
72.9±19.6a
Platelets (×109)
21.2±6.5
42.3±7.7ac
22.2±6.8
39.4±6.3a
Table 3 Changes in the peripheral blood of patients in the experimental group and control group before and after treatment ( xˉ ±s)
Notes: the experimental group was treated with Busuishengxue granules (15 g/bag) three times daily. The control group was treated with
Zaizaoshengxue tablets (5 tablets on each occasion, three times daily). Both groups were treated for 3 months as one course. A follow-up of
12 months was conducted. WBC: white blood cells; HB: Hemoglobin. Group comparison before and after treatment is given by aP<0.05,
and comparison between groups after treatment by bP<0.05 and cP>0.05.
Figure 1 Intracellular concentration of calcium ions in bone marrowmononuclear cells
FSC: forward scatter; FL1: fluorescence channel first; SSC: side scatter.
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Group
Experimental
Control
n
30
30
Treatment
Before treatment
After treatment
Before treatment
After treatment
Symptom score
18±5
7±5ab
18±5
11±5a
Table 2 Mean symptom scores of the experimental group
and control group ( xˉ ±s)
Notes: the experimental group was treated with Busuishengxue
granules (15 g/bag) three times daily. The control group was
treated with Zaizaoshengxue Tablets (5 tablets on each occasion,
three times daily). Both groups were treated for 3 months as one
course. A follow-up of 12 months was conducted. Group com-
parison before and after treatment is denoted by aP<0.05, and
comparison between groups by bP<0.05.
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that before treatment (P<0.05). There was a significant
difference between the experimental group and control
group after treatment (P<0.05), as well as compared
with the normal group (P<0.05).
Expression of p-JNK protein in BMMCs of the experi-
mental group and control group before treatment was
significantly higher than that of the normal group (P<
0.05, Table 8). After treatment, expression of p-JNK
protein in the experimental group and control group
decreased, and differed significantly to that before treat-
ment (P<0.05). There was an obvious difference be-
tween the experimental group and control group after
treatment (P<0.05), and a significant difference was
noted compared with the normal group (P<0.05).
Expression of p-p38 protein in BMMCs of the experi-
mental group and control group before treatment was
significantly higher than that of the normal group (P<
0.05, Table 9). After treatment, expression of p-p38
protein in the experimental group and control group
decreased, and differed significantly to that before treat-
ment (P<0.05). There was no remarkable difference be-
Group
Experimental
Control
Normal
n
30
30
10
[Ca2+]i
Before treatment
355±44ab
354±45 a
199±32
After treatment
253±43acd
298±48ac
-
Table 4 Distribution of calcium ions and levels of bone mar-
row mononuclear cells in the experimental group and con-
trol group before and after treatment ( xˉ ±s)
Notes: the experimental group was treated with Busuishengxue
granules (15 g/bag) three times daily. The control group was
treated with Zaizaoshengxue tablets (5 tablets on each occasion,
three times daily). Both groups were treated for 3 months as one
course. A follow-up of 12 months was conducted. Normal
group were volunteers without any treatment. Comparison with
the normal group is denoted by aP<0.05; before treatment, the
inter-group comparison is denoted by bP>0.05; group compari-
son before and after treatment is denoted by cP<0.05; after treat-
ment, the inter-group comparison is denoted by dP<0.05.
Group
Experimental
Control
Normal
n
30
30
10
p-ERK1/2 (grayscale analyses)
Before treatment
0.93±0.19ab
0.89±0.25a
1.59±0.17
After treatment
1.24±0.21acd
1.05±0.25ac
-
Table 5 Expression of p-ERK1/2 protein in the experimental
group and control group before and after treatment ( xˉ ±s)
Notes: the experimental group was treated with Busuishengxue
granules (15 g/bag) three times daily. The control group was
treated with Zaizaoshengxue tablets (5 tablets on each occasion,
three times daily). Both groups were treated for 3 months as one
course. A follow-up of 12 months was conducted. Normal
group were volunteers without any treatment. p-ERK1/2: p-ex-
tracellular signal regulated kinase 1/2. Comparison with the nor-
mal group is denoted by aP<0.05; comparison between groups
before treatment is denoted by bP>0.05; group comparison be-
fore and after treatment is denoted by cP<0.05; comparison be-
tween groups after treatment is denoted by dP<0.05.
Table 6 Expression of ERK1/2 protein in bone marrow mono-
nuclear cells of the experimental group and control group
before and after treatment ( xˉ ±s)
Group
Experimental
Control
Normal
n
30
30
10
ERK1 (grayscale analyses)
Before treatment
5.96±0.28ab
5.46±0.31a
9.50±0.13
After treatment
7.95±0.32cdf
6.94±0.37ae
-
Notes: the experimental group was treated with Busuishengx-
ue granules (15 g/bag) three times daily. The control group
was treated with Zaizaoshengxue tablets (5 tablets on each oc-
casion, three times daily). Both groups were treated for 3
months as one course. A follow-up of 12 months was conduct-
ed. Normal group were volunteers without any treatment.
ERK1: extracellular signal regulated kinase 1. Compared with
the normal group is denoted by cP<0.05 and aP<0.01; compar-
ison before treatment is denoted by dP<0.05 and eP>0.05;
comparison with the control group is denoted by fP<0.05 and
bP>0.05.
Group
Experimental
Control
Normal
n
30
30
10
ERK2 (grayscale analyses)
Before treatment
3.68±0.31a
3.71±0.28a
6.62±0.13
After treatment
5.84±0.32abc
4.21±0.31ab
-
Notes: the experimental group was treated with Busuishengxue
granules (15 g/bag) three times daily. The control group was
treated with Zaizaoshengxue tablets (5 tablets on each occasion,
three times daily). Both groups were treated for 3 months as one
course. A follow-up of 12 months was conducted. Normal
group were volunteers without any treatment. ERK 2: extracellu-
lar regulated kinase 2. Comparison with the normal group is de-
noted by aP<0.05; comparison with before treatment is denoted
by bP<0.05; comparison with the control group is denoted by cP<
0.05.
Table 7 Expression of ERK2 protein in bone marrowmononu-
clear cells of the experimental group and control group be-
fore and after treatment ( xˉ ±s)
Table 8 Expression of p-JNK protein in bone marrow mono-
nuclear cells of the experimental group and control group
before and after treatment ( xˉ ±s)
Group
Experimental
Control
Normal
n
30
30
10
p-JNK (grayscale analyses)
Before treatment
1.27±0.22a
1.28±0.21a
0.89±0.20
After treatment
0.98±0.22abc
1.12±0.24ab
-
Notes: the experimental group was treated with Busuishengxue
granules (15 g/bag) three times daily. The control group was
treated with Zaizaoshengxue tablets (5 tablets on each occasion,
three times daily). Both groups were treated for 3 months as one
course. A follow-up of 12 months was conducted. Normal
group were volunteers without any treatment. p-JNK: p-c-Jun
N-terminal kinases. Comparison with the normal group is de-
noted by aP<0.05 and bP>0.05; group comparison before and af-
ter treatment is denoted by cP<0.05.
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tween the experimental group and normal group after
treatment (P>0.05), but there was a significant differ-
ence between the experimental group and control
group after treatment (P<0.05).
Expression of p-ERK5 protein in the experimental
group and control group was significantly lower than
that of the normal group before treatment (P<0.05, Ta-
ble 10). Expression of p-ERK5 protein in the experi-
mental group and control group increased after treat-
ment, and was significantly different from that before
treatment (P<0.05). There was an obvious difference
between the experimental group and control group af-
ter treatment (P<0.05), and a significant difference was
noted compared with the normal group (P<0.05).
DISCUSSION
When evaluating clinical efficacy, we found that the to-
tal efficacy of Busuishengxue granules and Zaizaosh-
engxue tablets was 80.0% and 53.3% (P<0.05) respec-
tively. Busuishengxue granules had a better effect on
symptom scores and increasing the number of leuko-
cytes and HB levels in peripheral blood than Zaizaosh-
engxue tablets, whereas they differed slightly with re-
gard to increasing the number of platelets.
Adhesion molecules can be divided by structure into
the integrin family, Ig superfamily, selectin, cadherin,
glycoprotein, CD44 and sialomucin. There are three
mechanisms of cell adhesion. The first is mutual recog-
nition and binding of the same cell adhesion molecule
on two adjacent cell surfaces. The second is mutual rec-
ognition and binding of different cell adhesion mole-
cules on two adjacent cell surfaces. The third type is
mutual recognition and binding of the same cell adhe-
sion molecule on two adjacent cell surfaces by means
of extracellular linker molecules.
Integrins deliver membrane molecules that transduce
signals in a special way. Hence, several cell phenotypes
can be altered by integrins, such as the growth, differ-
entiation, migration, invasion and apoptosis of cells.13,14
By combination with different ligands, various signal
transduction pathways can be activated by an integrin.
The major signal transduction pathways are the tyro-
sine kinase-dependent pathways: the focal adhesion ki-
nase (FAK) pathway and Shc pathway. There may be
many types of signal transduction pathways after integ-
rins activate the FAK pathway. The FAK-Ras-MAPK
pathway has been studied quite comprehensively and
involves two aspects. First, after the combination of
FAK and Src, Crk-associated substrate (Cas) and paxil-
lin can be phosphorylated. After phosphorylation of
their butyric-acid moieties, they can adjust the cytoskel-
eton and produce domain proteins containing Src ho-
mology-2 (SH2), such as the binding site of Crk
(CT2102-regulated kinase). Thus, the Ras/MAPK
pathway can be activated via Crk. Second, Tyr925
phosphorylation of FAKs is caused by a combination
of FAK and Src, thereby providing the adapter protein
Grb2 with a binding site; the Src homology-3 (SH3)
of Grb2 can be linked with son of sevenless (SOS).
The SOS protein is a guanine nucleotide exchange fac-
tor that connects with the receptor phosphorylated in
tyrosine residues via connexin Grb2. Therefore,
through Grb2, FAKs can also activate the Ras/MAPK
pathway. The activated MAPK can activate many tran-
scription factors and mediate the activity expressed by
the FAK regulator gene.13-15
Our experimental results showed abnormal expression
of the enzymes of the signal transduction pathway relat-
ed to the BMMCs of NSAA patients. This expression
was significantly different from that of normal sub-
jects. Our data suggested that NSSA patients had an
abnormal Ras/MAPK pathway. Before treatment, ex-
pression of p-ERK1, p-ERK2, p-ERK1/2 and p-ERK5
was lower than that of normal controls, whereas expres-
sion of JNK and p-p38 as well as [Ca2 + ]i was higher
than those of normal controls. These data suggested ab-
normal adhesion signals in the blood cells of NSAA pa-
tients.
Table 9 Expression of p-p38 protein in bone marrow mono-
nuclear cells of the experimental group and control group
before and after treatment ( xˉ ±s)
Group
Experimental
Control
Normal
n
30
30
10
p-p38 (grayscale analyses)
Before treatment
2.32±0.15a
2.35±0.22a
1.88±0.13
After treatment
1.93±0.16bcd
2.19±0.23ac
-
Notes: the experimental group was treated with Busuishengxue
granules (15 g/bag) three times daily. The control group was
treated with Zaizaoshengxue tablets (5 tablets on each occasion,
three times daily). Both groups were treated for 3 months as one
course. A follow-up of 12 months was conducted. Normal
group were volunteers without any treatment. Comparison with
the normal group is denoted by aP<0.05 and bP>0.05; group
comparison before and after treatment is denoted by cP<0.05;
comparison with the control group after treatment is denoted by
dP<0.05.
Table 10 Expression of p-ERK5 protein in bone marrow
mononuclear cells of the experimental group and control
group before and after treatment ( xˉ ±s)
Group
Experimental
Control
Normal
n
30
30
10
p-ERK5 (grayscale analyses)
Before treatment
0.65±0.25a
0.63±0.21a
1.87±0.56
After treatment
1.57±0.30abc
1.25±0.36ab
-
Notes: the experimental group was treated with Busuishengxue
granules (15 g/bag) three times daily. The control group was
treated with Zaizaoshengxue tablets (5 tablets on each occasion,
three times daily). Both groups were treated for 3 months as one
course. A follow-up of 12 months was conducted. Normal
group were volunteers without any treatment. p-ERK5: p-extra-
cellular signal regulated kinase 5. Comparison with the normal
group is denoted by aP<0.05; comparison in the group before
and after treatment is denoted by bP<0.05; comparison with the
control group after treatment is denoted by cP<0.05.
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After treatment, expression of p-ERK1, p-ERK2,
p-ERK1/2 and p-ERK5 of NSAA patients increased to
different degrees. Expression of JNK and p-p38 was
down-regulated and [Ca2+]i reduced to different degrees
but, after treatment, except for p-p38 (P<0.05), the in-
dices in the experimental group were still significantly
different from those of the normal group.
We inferred from previous studies that the abnormal
expression of integrins from the VLA subfamily may re-
sult from the abnormal expression of enzymes of the in-
tracellular signal pathway mediated by them. That is,
abnormal intracellular signaling pathways may lead to
abnormal adhesion molecules being expressed on the
surface of BMMCs as well as expression of abnormal li-
gands. These events could affect the normal "homing"
of hematopoietic cells in the BM, and affect their dif-
ferentiation, proliferation and apoptosis, thereby lead-
ing to NSAA.
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